To circumvent these issues, we evaluated the BR.21 NCIC-CTG Phase III clinical trial of the EGFR-TKI inhibitor tarceva as a single agent in non-small cell lung carcinoma patients [46]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.